Kisqali FDA Approved Drugs
KISQALI [Ribociclib SuccinateC23H30N8OC4H6O4]
RX
- eq 200mg base (oral tablet)
Novartis Pharms CorpMar 13, 2017
- In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer.
KISQALI FEMARA CO-PACK (COPACKAGED) [LetrozoleC17H11N5 : Ribociclib SuccinateC23H30N8OC4H6O4]
RX
- 2.5mg,n/a : n/a,eq 200mg base (oral tablet, tablet)
Novartis Pharms CorpMay 4, 2017
- In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer.
WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.